CVRx, Inc. CVRX

CVRX Company Overview

CVRx, Inc. is a U.S.-based medical device company focused on developing and commercializing neuromodulation therapies for patients with cardiovascular diseases, particularly heart failure and hypertension. The company operates within the cardiovascular medical technology and bioelectronic medicine industries. Its primary commercial product is the Barostim platform, an implantable neuromodulation system designed to improve symptoms and quality of life in patients with heart failure by activating the body’s baroreflex system. Revenue is primarily generated through sales of implantable devices, related procedural components, and physician adoption within hospital systems.

The company’s key customer base includes hospitals, cardiovascular centers, electrophysiologists, vascular surgeons, and heart failure specialists, primarily in the United States and selected international markets. CVRx has positioned itself within a specialized segment of cardiac care by focusing on device-based autonomic nervous system modulation, differentiating itself from pharmaceutical-only approaches to heart failure management. Founded in 2001 and headquartered in Minneapolis, Minnesota, the company spent much of its early history developing and clinically validating baroreflex activation therapy before receiving major regulatory approvals, including U.S. FDA approval for the Barostim Neo System for heart failure patients in 2019.